{"id":501397,"date":"2021-06-07T09:15:08","date_gmt":"2021-06-07T13:15:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/neovasc-reducer-system-receives-first-national-reimbursement-in-europe\/"},"modified":"2021-06-07T09:15:08","modified_gmt":"2021-06-07T13:15:08","slug":"neovasc-reducer-system-receives-first-national-reimbursement-in-europe","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neovasc-reducer-system-receives-first-national-reimbursement-in-europe\/","title":{"rendered":"Neovasc Reducer System Receives First National Reimbursement in Europe"},"content":{"rendered":"
\n

\n
\n NHS England Provides National Coverage<\/i>
\n <\/b>\n <\/p>\n

VANCOUVER and MINNEAPOLIS, June 07, 2021 (GLOBE NEWSWIRE) — via NewMediaWire<\/a> \u2013 Neovasc<\/a> Inc. (\u201cNeovasc\u201d or the \u201cCompany\u201d) (NASDAQ<\/a>, TSX<\/a>: NVCN) today announced that the Neovasc Reducer\u00ae (\u201cReducer\u201d) system has been granted national reimbursement in England as a result of being included in the High-Cost Tariff Excluded Devices (HCTED) national catalogue.<\/p>\n

The National Health Service England (NHS England) has a nationwide purchase and supply system for specific categories of high-cost tariff-excluded medical devices used in specialized services designed to support the accelerated adoption of effective new technologies. These are devices NHS England has agreed should be paid for separately from the national tariff for a medical procedure. Hospital providers can now order the Reducer and bill the cost of the device directly to NHS England.<\/p>\n

Prof. Jonathan Hill, MD, Consultant Interventional Cardiologist at Royal Brompton & Harefield NHS Foundation Trust, London, U.K., commented, \u201cThe clinical data on Reducer therapy, much of it developed in the UK, continues to demonstrate efficacy and excellent safety. Inclusion in the HCTED catalogue is an important step for Reducer therapy and will help new centers to begin utilizing the device. This is good news for the many patients suffering from refractory angina in the UK.\u201d<\/p>\n

\u201cExpanding reimbursement for Reducer to enable broader market access has been a cornerstone of the value creation strategy at Neovasc. We are pleased with the NHS decision that follows the positive American Medical Association decision to establish a new Category III CPT code to report the transcatheter implantation of a coronary sinus reduction device,\u201d stated Fred Colen, President and Chief Executive Officer of Neovasc. \u201cWe are honored that the NHS has assessed the Reducer as an effective new therapy for patients. The NHS is recognized as a leading authority on health and care excellence. Their decision will help accelerate the adoption of Reducer therapy in the UK and will benefit patients.\u201d<\/p>\n

\n About Reducer<\/b>\u00a0<\/p>\n

The Reducer is CE-marked in the European Union for the treatment of refractory angina, a painful and debilitating condition that occurs when the coronary arteries deliver an inadequate supply of blood to the heart muscle, despite treatment with standard revascularization or cardiac drug therapies. It affects millions of patients worldwide, who typically lead severely restricted lives as a result of their disabling symptoms, and its incidence is growing. The Reducer provides relief of angina symptoms by altering blood flow within the myocardium of the heart and increasing the perfusion of oxygenated blood to ischemic areas of the heart muscle. Placement of the Reducer is performed using a minimally invasive transvenous procedure that is\u00a0similar to\u00a0implanting a coronary stent and is completed in approximately 20 minutes.\u00a0<\/p>\n

While the Reducer is not approved for commercial use in the United States, the FDA granted Breakthrough Device designation to the Reducer in October 2018. This designation is granted by the FDA in order to expedite the development and review of a device that demonstrates compelling potential to provide a more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases. In addition, there must be no FDA approved treatments presently available, or the technology must offer significant advantages over existing approved alternatives.\u00a0<\/p>\n

Refractory angina, resulting in continued symptoms despite maximal medical therapy and without revascularization options, is estimated to affect 600,000 to 1.8 million Americans, with 50,000 to 100,000 new cases per year.\u00a0<\/p>\n

\n About Neovasc Inc.<\/b>\n <\/p>\n

Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include Reducer, for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and Tiara\u2122 for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe. For more information, visit: www.neovasc.com<\/a>.<\/p>\n

\n Investors<\/b>
\n
Mike Cavanaugh
Westwicke\/ICR
Phone: +1.646.877.9641
Mike.Cavanaugh@westwicke.com<\/a><\/p>\n

\n Media<\/b>
\n
Sean Leous
Westwicke\/ICR
Phone: +1.646.866.4012
Sean.Leous@westwicke.com<\/a><\/p>\n

\n Forward-Looking Statement Disclaimer<\/b>\n <\/p>\n

Certain statements in this news release contain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws that may not be based on historical fact. When used herein, the words “expect”, “anticipate”, “estimate”, “may”, “will”, “should”, “intend,” “believe”, and similar expressions, are intended to\u00a0identify forward-looking statements. Forward-looking statements may involve, but are not limited to, the continuation of clinical data on Reducer therapy demonstrating efficacy and excellent safety, inclusion of the Reducer in the HCTED catalogue helping new centers to begin utilizing the device, the NHS decision helping to accelerate the adoption of Reducer therapy in the UK and benefiting patients and the growing cardiovascular marketplace. Many factors and assumptions could cause the Company’s actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, the doubt about the Company\u2019s ability to continue as a going concern; risks related to the recent COVID-19 coronavirus outbreak or other health epidemics, which could significantly impact the Company\u2019s operations, sales or ability to raise capital or enroll patients in clinical trials and complete certain Tiara development milestones on the Company\u2019s expected schedule; risks relating to the Company\u2019s need for significant additional future capital and the Company\u2019s ability to raise additional funding; risks relating to the sale of a significant number of Common Shares; risks relating to the possibility that the Company\u2019s common shares (the \u201cCommon Shares\u201d) may be delisted from the Nasdaq or the TSX, which could affect their market price and liquidity; risks relating to the Company\u2019s conclusion that it did have effective internal control over financial reporting as of December 31, 2020 but not at December 31, 2019 and 2018; risks relating to the Common Share price being volatile; risks relating to the possibility that the Common Shares may be delisted from the Nasdaq or the TSX, which could affect their market price and liquidity; risks relating to the Company\u2019s significant indebtedness, and its effect on the Company\u2019s financial condition; risks relating to lawsuits that the Company is subject to, which could divert the Company\u2019s resources and result in the payment of significant damages and other remedies; risks relating to claims by third-parties alleging infringement of their intellectual property rights; risks relating to the Company\u2019s ability to establish, maintain and defend intellectual property rights in the Company\u2019s products; risks relating to results from clinical trials of the Company\u2019s products, which may be unfavorable or perceived as unfavorable; the Company\u2019s history of losses and significant accumulated deficit; risks associated with product liability claims, insurance and recalls; risks relating to use of the Company\u2019s products in unapproved circumstances, which could expose the Company to liabilities; risks relating to competition in the medical device industry, including the risk that one or more competitors may develop more effective or more affordable products; risks relating to the Company\u2019s ability to achieve or maintain expected levels of market acceptance for the Company\u2019s products, as well as the Company\u2019s ability to successfully build its in-house sales capabilities or secure third-party marketing or distribution partners; risks relating to the Company\u2019s ability to convince public payors and hospitals to include the Company\u2019s products on their approved products lists; risks relating to new legislation, new regulatory requirements and the efforts of governmental and third-party payors to contain or reduce the costs of healthcare; risks relating to increased regulation, enforcement and inspections of participants in the medical device industry, including frequent government investigations into marketing and other business practices; risks relating to the extensive regulation of the Company\u2019s products and trials by governmental authorities, as well as the cost and time delays associated therewith; risks relating to post-market regulation of the Company\u2019s products; risks relating to health and safety concerns associated with the Company\u2019s products and industry; risks relating to the Company\u2019s manufacturing operations, including the regulation of the Company\u2019s manufacturing processes by governmental authorities and the availability of two critical components of the Reducer; risks relating to the possibility of animal disease associated with the use of the Company\u2019s products; risks relating to the manufacturing capacity of third-party manufacturers for the Company\u2019s products, including risks of supply interruptions impacting the Company’s ability to manufacture its own products; risks relating to the Company\u2019s dependence on limited products for substantially all of the Company\u2019s current revenues; risks relating to the Company\u2019s exposure to adverse movements in foreign currency exchange rates; risks relating to the possibility that the Company could lose its foreign private issuer status under U.S. federal securities laws; risks relating to the possibility that the Company could be treated as a “passive foreign investment company”; risks relating to breaches of anti-bribery laws by the Company\u2019s employees or agents; risks relating to future changes in financial accounting standards and new accounting pronouncements; risks relating to the Company\u2019s dependence upon key personnel to achieve its business objectives; risks relating to the Company\u2019s ability to maintain strong relationships with physicians; risks relating to the sufficiency of the Company\u2019s management systems and resources in periods of significant growth; risks relating to consolidation in the health care industry, including the downward pressure on product pricing and the growing need to be selected by larger customers in order to make sales to their members or participants; risks relating to the Company\u2019s ability to successfully identify and complete corporate transactions on favorable terms or achieve anticipated synergies relating to any acquisitions or alliances; risks relating to conflicts of interests among the Company’s officers and directors as a result of their involvement with other issuers; and risks relating to anti-takeover provisions in the Company\u2019s constating documents which could discourage a third-party from making a takeover bid beneficial to the Company\u2019s shareholders.These risk factors and others relating to the Company are discussed in greater detail in the “Risk Factors” section of the Company’s Annual Information Form and in the Management’s Discussion and Analysis for the three months ended March 31, 2021 (copies of which may be obtained at www.sedar.com<\/a> or www.sec.gov<\/a>). The Company has no intention and undertakes no obligation to update or revise any forward-looking statements beyond required periodic filings with securities regulators, whether as a result of new information, future events or otherwise, except as required by law.<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

NHS England Provides National Coverage VANCOUVER and MINNEAPOLIS, June 07, 2021 (GLOBE NEWSWIRE) — via NewMediaWire \u2013 Neovasc Inc. (\u201cNeovasc\u201d or the \u201cCompany\u201d) (NASDAQ, TSX: NVCN) today announced that the Neovasc Reducer\u00ae (\u201cReducer\u201d) system has been granted national reimbursement in England as a result of being included in the High-Cost Tariff Excluded Devices (HCTED) national catalogue. The National Health Service England (NHS England) has a nationwide purchase and supply system for specific categories of high-cost tariff-excluded medical devices used in specialized services designed to support the accelerated adoption of effective new technologies. These are devices NHS England has agreed should be paid for separately from the national tariff for a medical procedure. Hospital providers can now order the Reducer and … <\/p>\n

Continue reading “Neovasc Reducer System Receives First National Reimbursement in Europe”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-501397","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nNeovasc Reducer System Receives First National Reimbursement in Europe - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neovasc-reducer-system-receives-first-national-reimbursement-in-europe\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neovasc Reducer System Receives First National Reimbursement in Europe - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NHS England Provides National Coverage VANCOUVER and MINNEAPOLIS, June 07, 2021 (GLOBE NEWSWIRE) — via NewMediaWire \u2013 Neovasc Inc. (\u201cNeovasc\u201d or the \u201cCompany\u201d) (NASDAQ, TSX: NVCN) today announced that the Neovasc Reducer\u00ae (\u201cReducer\u201d) system has been granted national reimbursement in England as a result of being included in the High-Cost Tariff Excluded Devices (HCTED) national catalogue. The National Health Service England (NHS England) has a nationwide purchase and supply system for specific categories of high-cost tariff-excluded medical devices used in specialized services designed to support the accelerated adoption of effective new technologies. These are devices NHS England has agreed should be paid for separately from the national tariff for a medical procedure. Hospital providers can now order the Reducer and … Continue reading "Neovasc Reducer System Receives First National Reimbursement in Europe"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/neovasc-reducer-system-receives-first-national-reimbursement-in-europe\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-07T13:15:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0OTYxNSM0MjI5NzY3IzUwMDA2ODg0Mw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neovasc-reducer-system-receives-first-national-reimbursement-in-europe\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neovasc-reducer-system-receives-first-national-reimbursement-in-europe\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Neovasc Reducer System Receives First National Reimbursement in Europe\",\"datePublished\":\"2021-06-07T13:15:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neovasc-reducer-system-receives-first-national-reimbursement-in-europe\\\/\"},\"wordCount\":1735,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neovasc-reducer-system-receives-first-national-reimbursement-in-europe\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0OTYxNSM0MjI5NzY3IzUwMDA2ODg0Mw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neovasc-reducer-system-receives-first-national-reimbursement-in-europe\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neovasc-reducer-system-receives-first-national-reimbursement-in-europe\\\/\",\"name\":\"Neovasc Reducer System Receives First National Reimbursement in Europe - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neovasc-reducer-system-receives-first-national-reimbursement-in-europe\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neovasc-reducer-system-receives-first-national-reimbursement-in-europe\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0OTYxNSM0MjI5NzY3IzUwMDA2ODg0Mw==\",\"datePublished\":\"2021-06-07T13:15:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neovasc-reducer-system-receives-first-national-reimbursement-in-europe\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neovasc-reducer-system-receives-first-national-reimbursement-in-europe\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neovasc-reducer-system-receives-first-national-reimbursement-in-europe\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0OTYxNSM0MjI5NzY3IzUwMDA2ODg0Mw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0OTYxNSM0MjI5NzY3IzUwMDA2ODg0Mw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neovasc-reducer-system-receives-first-national-reimbursement-in-europe\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neovasc Reducer System Receives First National Reimbursement in Europe\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Neovasc Reducer System Receives First National Reimbursement in Europe - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/neovasc-reducer-system-receives-first-national-reimbursement-in-europe\/","og_locale":"en_US","og_type":"article","og_title":"Neovasc Reducer System Receives First National Reimbursement in Europe - Market Newsdesk","og_description":"NHS England Provides National Coverage VANCOUVER and MINNEAPOLIS, June 07, 2021 (GLOBE NEWSWIRE) — via NewMediaWire \u2013 Neovasc Inc. (\u201cNeovasc\u201d or the \u201cCompany\u201d) (NASDAQ, TSX: NVCN) today announced that the Neovasc Reducer\u00ae (\u201cReducer\u201d) system has been granted national reimbursement in England as a result of being included in the High-Cost Tariff Excluded Devices (HCTED) national catalogue. The National Health Service England (NHS England) has a nationwide purchase and supply system for specific categories of high-cost tariff-excluded medical devices used in specialized services designed to support the accelerated adoption of effective new technologies. These are devices NHS England has agreed should be paid for separately from the national tariff for a medical procedure. Hospital providers can now order the Reducer and … Continue reading \"Neovasc Reducer System Receives First National Reimbursement in Europe\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/neovasc-reducer-system-receives-first-national-reimbursement-in-europe\/","og_site_name":"Market Newsdesk","article_published_time":"2021-06-07T13:15:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0OTYxNSM0MjI5NzY3IzUwMDA2ODg0Mw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neovasc-reducer-system-receives-first-national-reimbursement-in-europe\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neovasc-reducer-system-receives-first-national-reimbursement-in-europe\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Neovasc Reducer System Receives First National Reimbursement in Europe","datePublished":"2021-06-07T13:15:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neovasc-reducer-system-receives-first-national-reimbursement-in-europe\/"},"wordCount":1735,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neovasc-reducer-system-receives-first-national-reimbursement-in-europe\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0OTYxNSM0MjI5NzY3IzUwMDA2ODg0Mw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neovasc-reducer-system-receives-first-national-reimbursement-in-europe\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/neovasc-reducer-system-receives-first-national-reimbursement-in-europe\/","name":"Neovasc Reducer System Receives First National Reimbursement in Europe - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neovasc-reducer-system-receives-first-national-reimbursement-in-europe\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neovasc-reducer-system-receives-first-national-reimbursement-in-europe\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0OTYxNSM0MjI5NzY3IzUwMDA2ODg0Mw==","datePublished":"2021-06-07T13:15:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neovasc-reducer-system-receives-first-national-reimbursement-in-europe\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/neovasc-reducer-system-receives-first-national-reimbursement-in-europe\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neovasc-reducer-system-receives-first-national-reimbursement-in-europe\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0OTYxNSM0MjI5NzY3IzUwMDA2ODg0Mw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0OTYxNSM0MjI5NzY3IzUwMDA2ODg0Mw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neovasc-reducer-system-receives-first-national-reimbursement-in-europe\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Neovasc Reducer System Receives First National Reimbursement in Europe"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/501397","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=501397"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/501397\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=501397"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=501397"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=501397"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}